These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 12520782)

  • 1. [Use of dopamine analogs in Parkinson's disease treatment].
    Gekht AB
    Zh Nevrol Psikhiatr Im S S Korsakova; 2002; 102(12):53-5. PubMed ID: 12520782
    [No Abstract]   [Full Text] [Related]  

  • 2. [Use of pronoran (piribedil) in Parkinson's disease: the results of a multicenter study].
    Fedorova NV
    Zh Nevrol Psikhiatr Im S S Korsakova; 2003; 103(11):21-4. PubMed ID: 14681961
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Treatment of Parkinson's disease: use of piribedil].
    Gekht AB
    Zh Nevrol Psikhiatr Im S S Korsakova; 2004; 104(1):54-6. PubMed ID: 14870695
    [No Abstract]   [Full Text] [Related]  

  • 4. Piribedil--an oral dopamine agonist for treatment of Parkinson's disease.
    Sweet RD; Wasterlain C; McDowell FH
    Trans Am Neurol Assoc; 1974; 99():258-60. PubMed ID: 4463553
    [No Abstract]   [Full Text] [Related]  

  • 5. [The effectiveness and tolerance of piribedil as adjunct therapy to levodopa in patients with Parkinson's disease: a nine month follow up].
    Salazar Tortolero G; Wix Ramos R; Salazar Aladrén P; Jiménez León JC
    Rev Neurol; 2004 Apr 16-30; 38(8):715-9. PubMed ID: 15122540
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dopamine receptor stimulating agonists in the treatment of Parkinson's disease.
    Agid Y; Barroche G; Bonnet AM; Javoy-Agid F; Kato G; Lhermitte F; Pollak P; Signoret JL
    Biomedicine; 1979 Jun; 30(2):67-71. PubMed ID: 383169
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The agonist of dopamine receptors piribedil in treatment of Parkinson's disease].
    Pilipovich AA; Golubev VL
    Zh Nevrol Psikhiatr Im S S Korsakova; 2017; 117(6):83-90. PubMed ID: 28745677
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current status of dopamine agonists in Parkinson's disease management.
    Montastruc JL; Rascol O; Senard JM
    Drugs; 1993 Sep; 46(3):384-393. PubMed ID: 7693430
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Parkinson-Control study: a 1-year randomized, double-blind trial comparing piribedil (150 mg/day) with bromocriptine (25 mg/day) in early combination with levodopa in Parkinson's disease.
    Castro-Caldas A; Delwaide P; Jost W; Merello M; Williams A; Lamberti P; Aguilar M; Del Signore S; Cesaro P;
    Mov Disord; 2006 Apr; 21(4):500-9. PubMed ID: 16267842
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The dopamine agonist piribedil with L-DOPA improves attentional dysfunction: relevance for Parkinson's disease.
    Turle-Lorenzo N; Maurin B; Puma C; Chezaubernard C; Morain P; Baunez C; Nieoullon A; Amalric M
    J Pharmacol Exp Ther; 2006 Nov; 319(2):914-23. PubMed ID: 16920993
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Factors influencing dopaminergic therapy of Parkinson's disease.
    Horowski R
    Funct Neurol; 1988; 3(4):459-70. PubMed ID: 2907501
    [No Abstract]   [Full Text] [Related]  

  • 12. [Dopaminergic agonists in Parkinson disease].
    Dubois B; Agid Y
    Rev Prat; 1986 Jan; 36(5):207-14. PubMed ID: 3961400
    [No Abstract]   [Full Text] [Related]  

  • 13. Piribedil (ET 495) in the treatment of Parkinson's disease combined with amantadine or levodopa.
    Callaghan N; Fitzpatrick E; O'Mahony JB
    Acta Neurol Scand; 1975 Sep; 52(3):179-86. PubMed ID: 1098359
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Updates in practical neurology--I. The principles of modern levodopa therapy in Parkinson's disease].
    Klivényi P; Vécsei L
    Ideggyogy Sz; 2007 Jan; 60(1-2):61-4. PubMed ID: 17432097
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Piribedil: its synergistic effect in multidrug regimens for parkinsonism.
    Feigenson JS; Sweet RD; McDowell FH
    Neurology; 1976 May; 26(5):430-3. PubMed ID: 944394
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High concentration of plasma methoxytyramine: dopamine-producing tumour or Parkinson's disease therapy?
    Chtioui H; Sadowski SM; Winzeler B; Tschopp O; Grouzmann E; Abid K
    Ann Clin Biochem; 2019 Jul; 56(4):466-471. PubMed ID: 30974961
    [No Abstract]   [Full Text] [Related]  

  • 17. Dopaminergic agonist effects on Parkinsonian clinical features and brain monamine metabolism.
    Rinne UK; Sonninen V; Marttila R
    Adv Neurol; 1975; 9():383-92. PubMed ID: 1096575
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Piribedil in the treatment of Parkinson disease (author's transl)].
    Nardini M; Sciannandrone R; Fieschi C; De Simone G
    Riv Patol Nerv Ment; 1975; 96(2):103-10. PubMed ID: 778998
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The concept of continuous dopaminergic stimulation in the treatment of late stages of Parkinson's disease].
    Titova NV; Katunina EA
    Zh Nevrol Psikhiatr Im S S Korsakova; 2013; 113(12):105-12. PubMed ID: 24596973
    [No Abstract]   [Full Text] [Related]  

  • 20. Treatment of Parkinson's with L-DOPA. The early discovery phase, and a comment on current problems.
    Carlsson A
    J Neural Transm (Vienna); 2002 May; 109(5-6):777-87. PubMed ID: 12111467
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.